PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31201197-0	2019	Correction: Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study).	Tramadol	12-20	translocation associated membrane protein 1	Homo sapiens	36-40	
33575951-1	2021	INTRODUCTION: Recently the DAVID study demonstrated the better analgesic efficacy of tramadol hydrochloride/dexketoprofen 75/25 mg (TRAM/DKP) over tramadol hydrochloride/paracetamol 75/650 mg (TRAM/paracetamol) in a model of moderate to severe acute pain following surgical removal of an impacted third molar.	Tramadol	85-107	translocation associated membrane protein 1	Homo sapiens	132-136	
33575951-1	2021	INTRODUCTION: Recently the DAVID study demonstrated the better analgesic efficacy of tramadol hydrochloride/dexketoprofen 75/25 mg (TRAM/DKP) over tramadol hydrochloride/paracetamol 75/650 mg (TRAM/paracetamol) in a model of moderate to severe acute pain following surgical removal of an impacted third molar.	Tramadol	85-107	translocation associated membrane protein 1	Homo sapiens	193-197	
31535328-1	2019	INTRODUCTION: In 2016, the orally administered fixed-dose combination of dexketoprofen 25 mg and tramadol 75 mg (DKP/TRAM FDC) was approved in Europe for short-term treatment of moderate-to-severe acute pain, an indication that encompasses a wide range of post-operative and non-surgical painful conditions.	Tramadol	97-105	translocation associated membrane protein 1	Homo sapiens	117-121	
30782886-0	2019	Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study).	Tramadol	0-8	translocation associated membrane protein 1	Homo sapiens	24-28	
30675632-10	2019	SR-TRAM had the highest mean doses and durations, followed by immediate release formulations of tramadol (IR-TRAM) and COMB.	Tramadol	96-104	translocation associated membrane protein 1	Homo sapiens	109-113	
28799579-2	2017	A tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed combination (TRAM/DKP 75 mg/25 mg) has been recently registered and released in Europe for the treatment of moderate-to-severe acute pain.	Tramadol	2-24	translocation associated membrane protein 1	Homo sapiens	75-79	
30117229-13	2018	Tramadol had a C50, TRAM of 0.07 (95%CI 0.048, 1.07) mg/L with a t1/2 keo,TRAM 1.78 hour (95%CI 1.06, 1.96).	Tramadol	0-8	translocation associated membrane protein 1	Homo sapiens	20-24	
30117229-13	2018	Tramadol had a C50, TRAM of 0.07 (95%CI 0.048, 1.07) mg/L with a t1/2 keo,TRAM 1.78 hour (95%CI 1.06, 1.96).	Tramadol	0-8	translocation associated membrane protein 1	Homo sapiens	74-80	
27531573-3	2016	Conversely, tramadol hydrochloride/acetaminophen combination (TRAM/APAP) therapy has been shown to reduce pain, particularly for chronic pain in Japan.	Tramadol	12-34	translocation associated membrane protein 1	Homo sapiens	62-66